×
For best experience we recommend to activate Javascript in your browser.
Recombinant LAG3 antibody (AA 23-434)
The Llama Monoclonal anti-LAG3 antibody has been validated for ELISA, FACS, IHC (p) and IF. It is suitable to detect LAG3 in samples from Human.
Quick Overview for Recombinant LAG3 antibody (AA 23-434) (ABIN7541353)
Target
See all LAG3 Antibodies
LAG3
(Lymphocyte-Activation Gene 3 (LAG3))
Antibody Type
Recombinant Antibody
Fragment
single-domain Antibody (sdAb)
Reactivity
All reactivities for LAG3 antibodies
Human
Host
All hosts for LAG3 antibodies
Llama
Clonality
All clonalities for LAG3 antibodies
Monoclonal
Conjugate
All conjugates for LAG3 antibodies
This LAG3 antibody is un-conjugated
Application
All applications for LAG3 antibodies
ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)
Clone
1A61A6
Product Details anti-LAG3 Antibody
(hide)
Binding Specificity
All epitopes for LAG3 antibodies
AA 23-434
Expression System
Mammalian cells
Purpose
Llama recombinant monoclonal antibody raised against human LAG3.
Cross-Reactivity
Human
Immunogen
Original antibody is raised against recombinant protein corresponding to the amino acids 23-434 of human LAG3.
Alternatives
(show)
Application Details
(hide)
Application Notes
ELISA (start at 0.1 μg/mL),Flow Cytometry (start at 1 μg/mL),Immunofluorescence (start at 5 μg/mL),Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (start at 1 μg/mL),The optimal working dilution should be determined by the
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
In PBS
Storage
-20 °C
Storage Comment
Store at -20°C for 1 year. Aliquot to avoid repeated freezing and thawing.
Target Details for LAG3
(hide)
Target
LAG3
(Lymphocyte-Activation Gene 3 (LAG3))
Alternative Name
LAG3
Background
Lymphocyte-activation gene 3
Gene ID
3902
Pathways
Regulation of Leukocyte Mediated Immunity , Positive Regulation of Immune Effector Process , Cancer Immune Checkpoints
Recently viewed
(hide)
Chat with us , powered by LiveChat